XML 42 R28.htm IDEA: XBRL DOCUMENT
v3.23.2

Revenue from Contracts with Customers (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Schedule of Contract Assets and Contract Liabilities | Total contract assets at June 30, 2023 were as follows:
(In thousands) |  | Contract Assets |
Contract assets at December 31, 2022 |  | $ | 8,929 |
Additions |  |  | 10,115 |
Transferred to receivables, net |  |  | (19,044 | )
Contract assets at June 30, 2023 |  | $ | — |
Total contract liabilities at June 30, 2023 were as follows:
(In thousands) |  | Contract Liabilities |
Contract liabilities at December 31, 2022 |  | $ | 10,701 |
Additions |  |  | (932 | )
Amounts recognized into revenue |  |  | (4,101 | )
Contract liabilities at June 30, 2023 |  | $ | 5,668 |
Product sales, net |
Schedule of Disaggregation of Revenues | During the three and six months ended June 30, 2023 and 2022, the Company recorded product sales, net, as follows:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(In thousands) |  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
VIVITROL |  | $ | 102,071 |  |  | $ | 96,105 |  |  | $ | 198,730 |  |  | $ | 180,959 |
ARISTADA and ARISTADA INITIO |  |  | 82,409 |  |  |  | 74,622 |  |  |  | 162,486 |  |  |  | 147,107 |
LYBALVI |  |  | 46,997 |  |  |  | 20,060 |  |  |  | 84,988 |  |  |  | 33,989 |
Total product sales, net |  | $ | 231,477 |  |  | $ | 190,787 |  |  | $ | 446,204 |  |  | $ | 362,055 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the three and six months ended June 30, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|  | Three Months Ended June 30, 2023 |  |  | Six Months Ended June 30, 2023 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 321,239 |  |  | $ | 321,239 |  |  | $ | — |  |  | $ | 334,801 |  |  | $ | 334,801 |
VUMERITY |  |  | 10,369 |  |  |  | 21,926 |  |  |  | 32,295 |  |  |  | 23,018 |  |  |  | 38,151 |  |  |  | 61,169 |
RISPERDAL CONSTA |  |  | 4,901 |  |  |  | 240 |  |  |  | 5,141 |  |  |  | 15,317 |  |  |  | 806 |  |  |  | 16,123 |
Other |  |  | 16,628 |  |  |  | 10,610 |  |  |  | 27,238 |  |  |  | 32,003 |  |  |  | 14,679 |  |  |  | 46,682 |
|  | $ | 31,898 |  |  | $ | 354,015 |  |  | $ | 385,913 |  |  | $ | 70,338 |  |  | $ | 388,437 |  |  | $ | 458,775 |
|  | Three Months Ended June 30, 2022 |  |  | Six Months Ended June 30, 2022 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 26,648 |  |  | $ | 26,648 |  |  | $ | — |  |  | $ | 63,702 |  |  | $ | 63,702 |
VUMERITY |  |  | 5,650 |  |  |  | 20,520 |  |  |  | 26,170 |  |  |  | 17,045 |  |  |  | 39,720 |  |  |  | 56,765 |
RISPERDAL CONSTA |  |  | 8,571 |  |  |  | 1,820 |  |  |  | 10,391 |  |  |  | 24,149 |  |  |  | 3,668 |  |  |  | 27,817 |
Other |  |  | 11,353 |  |  |  | 10,764 |  |  |  | 22,117 |  |  |  | 23,207 |  |  |  | 19,005 |  |  |  | 42,212 |
|  | $ | 25,574 |  |  | $ | 59,752 |  |  | $ | 85,326 |  |  | $ | 64,401 |  |  | $ | 126,095 |  |  | $ | 190,496 |
(1) “Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |